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Background. Although only 8%–10% of persons infected 
with human T-cell leukemia virus type 1 (HTLV-1) may de-
velop virus-associated diseases lifelong, misdiagnosis of asymp-
tomatic infected carriers frequently leads to late diagnoses.
Methods. A nationwide HTLV-1 register was created in 
Spain in 1989. A total of 351 infected persons had been reported 
by the end of 2017. We examined all new HTLV-1 diagnoses 
during the last decade and compared their clinical presentation.
Results. A total of 247 individuals with HTLV-1 infection had 
been reported in Spain since year 2008. The incidence has remained 
stable with 20–25 new diagnoses yearly. Women represented 62%. 
Only 12% were native Spaniards, most of whom were foreigners 
from Latin America (72.5%). Up to 57 (23%) individuals presented 
clinically with HTLV-1-associated conditions, including subacute 
myelopathy (n = 24; 42.1%), T-cell lymphoma (n = 19; 33.3%), or 
Strongyloides stercoralis infestation (n  =  8; 14%). Human T-cell 
leukemia virus type 1 diagnosis had been made either at blood 
banks (n = 109; 44%) or at clinics (n = 138; 56%). It is interesting to 
note that Spaniards and especially Africans were overrepresented 
among patients presenting with HTLV-1-associated illnesses, sug-
gesting that misdiagnosis and late presentation are more frequent 
in these populations compared to Latin Americans.
Conclusions. Given that 23% of new HTLV-1 diagnoses 
in Spain are symptomatic, underdiagnosis must be common. 
Although screening in blood banks mostly identifies asymp-
tomatic Latin American carriers, a disproportionately high 
number of Spaniards and Africans are unveiled too late, that is, 
they already suffer from classic HTLV-1 illnesses.
Keywords. adult T-cell leukemia; epidemiology; HTLV-1; 
myelopathy; screening.
Human T-cell leukemia virus type 1 (HTLV-1) was the first dis-
covered human retrovirus. It was isolated 50 years ago from a 
patient with a cutaneous T-cell lymphoma [1]. Approximately 
10–15 million people are estimated to be chronically infected 
with HTLV-1 worldwide [2, 3]. Highly endemic regions exist 
in the Caribbean and parts of Latin America, West Africa, 
Iran, Japan, and Romania. Within the European Union, most 
HTLV-1 infections are made in persons with black ethnicity 
from coming from either the Caribbean or sub-Saharan Africa 
[2–4]. The virus is mostly transmitted sexually [5], perinatally 
by breastfeeding [6], and parenterally throughout contaminated 
blood either after transfusions or needle sharing among injec-
tion drug users [7, 8].
Only 8%–10% of persons infected with HTLV-1 may develop 
2 characteristic-associated diseases [9–11]—namely, tropical 
spastic paraparesis (TSP), or HTLV-associated myelopathy 
(HAM), and adult T-cell leukemia/lymphoma (ATL)—during 
their lifetime. Misdiagnosis of asymptomatic HTLV-1 carriers 
frequently leads to late diagnoses. In this regard, the real burden 
of HTLV-1 infections in a region may be indirectly inferred from 
the number of people presenting with symptomatic illnesses.
METHODS
A nationwide HTLV-1 register and biological repository was 
created in Spain since 1989. More than 45 centers are members 
of the Spanish HTLV Network, distributed across the whole 
national geography. Participating centers and major epidemi-
ological findings have already been described elsewhere [12]. 
Uniform case report forms collecting demographics, epidemio-
logical features, clinical signs, and manifestations are filled out 
for each new diagnosis by the respective doctor in charge. On a 
yearly basis, a group meeting is arranged around mid December 
and new cases are presented and discussed by all members of 
the network.
Human T-cell leukemia virus testing in Spain is conducted 
at the microbiology departments of clinics/hospitals on de-
mand, only when there is clinical suspicion, and rarely as part 
of general screening for sexually transmitted infections or pre-
natal testing. In contrast, HTLV antibodies are examined man-
datorily in all transplants as well as in at-risk blood donors. 
Individuals diagnosed with HTLV-1 at blood banks are initially 
informed by the transfusion center medical staff and invited to 
attend appointments with infectious diseases specialists that are 
associated with the Spanish network at clinics located at dif-
ferent large cities.
A total of 351 individuals with HTLV-1 infection had been 
reported in Spain by the end of 2017. For the purpose of this 
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HTLV-1 infection diagnosed only during the last decade. Expert 
clinicians reviewed clinical charts and checked neurological 
and hematological signs/symptoms in particular. When pos-
sible, epidemiological information was tracked to determine 
the most likely routes of HTLV-1 transmission.
Statistical Analysis
All numerical variables are reported as absolute values and 
percentages. Categorical variables were compared using χ2 or 
Fisher exact tests, whereas noncategorical variables were com-
pared using Student t test or Mann-Whitney U tests. All analy-
ses were 2-tailed, and only P values below .05 were considered 
to be significant. All statistical analyses were performed using 
SPSS software, version 16.0 (SPSS Inc., Chicago, IL).
RESULTS
A total of 247 individuals with HTLV-1 infection had been re-
ported in Spain since 2008. Most cases were diagnosed around 
large urban areas (Madrid and Barcelona) where the largest im-
migrant populations live. Women represented 62%. Only 12% 
were native Spaniards, most of whom were foreigners from 
Latin America (72.5%). Africans represented 8.5%. It is in-
teresting to note that heterosexual exposure is the most likely 
source of HTLV-1 infection among native Spaniards, in most 
cases this was linked to partners from endemic regions in Latin 
America.
During this period, 57 (23%) individuals presented clini-
cally with HTLV-1-associated conditions, including TSP/HAM 
(n = 24; 42.1%), ATL (n = 19; 33.3%), and Strongyloides ster-
coralis infestation (n = 8; 14%), or other potentially linked con-
ditions, such as neuropathies, sicca syndrome, etc. In 4 (7%) of 
these symptomatic individuals, HTLV-1 was found as coinfec-
tion with human immunodeficiency virus-1.
One hundred nine subjects (44%) subjects were diagnosed 
with HTLV-1 at blood banks, and 138 (56%) subjects were diag-
nosed at clinics. As expected, blood donors with HTLV-1 infec-
tion were all asymptomatic, whereas 57 (41%) patients identified 
at clinics had HTLV-1-associated conditions at presentation. 
The main characteristics of these 2 populations are recorded in 
Table 1. Spaniards and especially Africans were overrepresented 
among hospital-based HTLV-1 diagnoses, suggesting that late 
presentation and misdiagnosis were more common in these 2 
groups compared with Latin Americans.
Table 2 records the main features of 57 HTLV-1-infected 
patients presenting with symptomatic illnesses, which were 
mostly neurological (61%) or hematological conditions (33%). 
Women were more frequently represented than men (65%), re-
gardless of clinical presentation. On the other hand, individuals 
presenting with TSP/HAM were on average 8 years older than 
those with ATL. Finally, although Spaniards presented more 
frequently with TSP/HAM than ATL (8 vs 2), the opposite 
occurred among Africans (3 vs 5).
It is interesting to note that a 54-year-old woman developed 
rapid-onset subacute paraparesis after kidney transplantation 
in 2015 from a cadaveric donor retrospectively known to be 
HTLV-1 positive [13]. In contrast, the recipient of the second 
kidney experienced early graft rejection that required surgical 
removal. The recipient discontinued immunosuppressants, and 
more than 2 years later he remains asymptomatic despite having 
been infected with HTLV-1.
DISCUSSION
A total of 247 individuals with HTLV-1 infection have been 
diagnosed in Spain during the last decade. The large immigrant 
flow from HTLV-1-endemic regions mostly accounts for this 
population, although native Spaniards represent 12% of cases. 
Overall, the relatively large proportion of symptomatic indi-
viduals (23.1%) suggests that HTLV-1 infection is frequently 
underdiagnosed in Spain.
Screening in Spanish blood banks mostly identified asymp-
tomatic Latin American carriers, whereas classic HTLV-1-
associated conditions such as TSP/HAM and ATL unexpectedly 
unveiled a disproportionately high number of HTLV-1 infec-
tions among Spaniards and Africans. In native Spaniards, 
late HTLV-1 diagnoses could largely be due to poor clinical 
Table 1. New HTLV-1 Diagnoses in Spain (2008–2017)
Variables Total Blood Donors Clinics P
N (%) 247 109 (44) 138 (56) n.s.
Female gender (%) 153 (62) 69 (63) 84 (61) n.s.
Median age (years) 43.4 42.6 44 n.s.
Country of Origin (%)
•  Spain 29 (12) 9 20 .09
•  Latin America 179 (72.5) 88 91 n.s.
•  Africa 21 (8.5) 1 20 <.01
•  Others 18 (7.3) 11 7 n.s.
HTLV symptomatic disease (%) 57 (23) 0 57 (41) <.01
HIV coinfection 4 (1.6) 0 4 (3) <.01
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suspicion in persons that had acquired the virus locally after 
sexual contacts with Latin Americans [14, 15]. This finding sup-
ports that HTLV-1 should no longer be neglected, and testing 
should be promoted at clinics for sexually transmitted infec-
tions [16]. In Africans, limited access to health services along 
with poor clinical and epidemiological suspicion in persons 
coming from endemic regions might have contributed to fre-
quent HTLV-1 misdiagnosis. Moreover, Africans are generally 
excluded in blood banks due to high rates of prior history of 
malaria and other tropical conditions. Therefore, they rarely 
would be identified as asymptomatic HTLV-1 blood donors.
More than half of new HTLV-1 diagnoses in Spain during 
the last decade were performed at clinics. Up to 41% of these 
patients had typical HTLV-1-associated illnesses, that is, either 
neurological or hematological conditions. Women were more 
frequently represented than men, regardless of clinical pre-
sentation. On average, individuals presenting with TSP/HAM 
were older than those with ATL. It is interesting to note that 
Spaniards more frequently presented with TSP/HAM than 
ATL, whereas Africans presented with ATL more often than 
with TSP/HAM. This finding is in agreement with the fact that 
HTLV-1-associated leukemias/lymphomas mostly develop in 
subjects infected perinatally from their mothers in highly en-
demic regions [17, 18]. Sexual transmission was by far the most 
likely route of HTLV-1 infection among native Spaniards.
To date, 4 individuals in the Spanish register had developed 
rapid-onset subacute myelopathy after solid organ transplanta-
tion from 2 separate donors retrospectively known to be HTLV-
1-positive. The first organ donor was reported in year 2000. He 
was a young male Spaniard, asymptomatic, with a Venezuelan 
mother who most likely transmitted the infection perinatally. 
All 3 recipients of the 2 kidneys and the liver, respectively, devel-
oped TSP within 18 months [19]. The second donor was 1 male 
Spaniard, asymptomatic, who most likely acquired HTLV-1 via 
sexual contact with a Brazilian partner. Although one of the 
donor’s kidney recipients developed TSP [13], another one who 
experienced early organ rejection and discontinued immuno-
suppressants has remained asymptomatic to date despite be-
coming infected with HTLV-1.
We should acknowledge several limitations of our study. 
First, given its retrospective study design, we could not be cer-
tain about the route of infection for a subset of individuals, 
and, likewise, some epidemiological information was missing. 
Second, given the voluntary reporting system, we could not 
totally exclude that some HTLV-1-positive persons diagnosed 
in Spain were not counted. However, we have a relatively good 
surveillance system, and we actively search and try to contact 
those doctors and departments where potential HTLV-1 cases 
or their relatives are medically attended.
CONCLUSIONS
In summary, our results show that the incidence of new HTLV-1 
infections in Spain during the last decade has remained rela-
tively stable at approximately 20–25 cases per year. Although 
Latin Americans and Africans represent more than 80% of cases, 
12% of new HTLV-1 diagnoses are native Spaniards. Moreover, 
Spaniards represent approximately 20% of all symptomatic 
HTLV-1 diagnoses. Altogether, late presentation and misdiag-
nosis should encourage wider HTLV-1 testing in Spain. Lessons 
from Spain may well apply to other countries with similar large 
immigration flows from Latin America. Human T-cell leukemia 
virus screening should be particularly favored in the following 
populations: (1) blood donors, given the relatively high number 
of Latin Americans coming from HTLV-1-endemic regions; (2) 
solid organ transplantation, given the frequent and high risk of 
rapid clinical progression [20, 21]; and pregnant women, given 
that perinatal HTLV-1 transmission to newborns can be effec-
tively avoided if breastfeeding is discouraged [15].
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